{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Capsule+2&page=61",
    "query": {
      "intervention": "Capsule 2",
      "page": 61
    },
    "page_size": 10
  },
  "pagination": {
    "page": 61,
    "page_size": 10,
    "total_count": 5060,
    "total_pages": 506,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Capsule+2&page=62&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Capsule+2&page=60&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-10T12:13:12.483Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07757568",
      "title": "Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis (MS) Relapsing Remitting"
      ],
      "interventions": [
        {
          "name": "Vumerity",
          "type": "DRUG"
        },
        {
          "name": "Tecfidera",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2023-03-07",
      "completion_date": "2026-11-07",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-11-10T12:13:12.483Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07757568"
    },
    {
      "nct_id": "NCT04161391",
      "title": "Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Medullary Thyroid Cancer",
        "RET Gene Mutation",
        "Metastatic Solid Tumor",
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "TPX-0046",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Turning Point Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2019-12-06",
      "completion_date": "2023-05-22",
      "has_results": true,
      "last_update_posted_date": "2024-06-13",
      "last_synced_at": "2026-11-10T12:13:12.483Z",
      "location_count": 20,
      "location_summary": "La Jolla, California • Orange, California • Aurora, Colorado + 15 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04161391"
    },
    {
      "nct_id": "NCT00838526",
      "title": "Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastroesophageal Reflux Disease (GERD)"
      ],
      "interventions": [
        {
          "name": "Rabeprazole ER",
          "type": "DRUG"
        },
        {
          "name": "Ranitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 240,
      "start_date": "2008-08-31",
      "completion_date": "2009-12-31",
      "has_results": true,
      "last_update_posted_date": "2022-04-25",
      "last_synced_at": "2026-11-10T12:13:12.483Z",
      "location_count": 4,
      "location_summary": "Moline, Illinois",
      "locations": [
        {
          "city": "Moline",
          "state": "Illinois"
        },
        {
          "city": "Moline",
          "state": "Illinois"
        },
        {
          "city": "Moline",
          "state": "Illinois"
        },
        {
          "city": "Moline",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00838526"
    },
    {
      "nct_id": "NCT04905043",
      "title": "A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Acalabrutinib",
          "type": "DRUG"
        },
        {
          "name": "SmartPill®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acerta Pharma BV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2016-06-03",
      "completion_date": "2016-07-11",
      "has_results": false,
      "last_update_posted_date": "2021-06-03",
      "last_synced_at": "2026-11-10T12:13:12.483Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04905043"
    },
    {
      "nct_id": "NCT02144415",
      "title": "A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Drug Users"
      ],
      "interventions": [
        {
          "name": "EB-1020 400 mg",
          "type": "DRUG"
        },
        {
          "name": "EB-1020 800 mg",
          "type": "DRUG"
        },
        {
          "name": "lisdexamfetamine 150 mg",
          "type": "DRUG"
        },
        {
          "name": "d-amphetamine 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 80,
      "start_date": "2014-05-01",
      "completion_date": "2014-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-11-10T12:13:12.483Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02144415"
    },
    {
      "nct_id": "NCT01569750",
      "title": "A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "CD20-positive B-cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Part 1, Cohort 1",
          "type": "DRUG"
        },
        {
          "name": "Part 1, Cohort 2",
          "type": "DRUG"
        },
        {
          "name": "Part 1, Cohort 3",
          "type": "DRUG"
        },
        {
          "name": "Part 2, Cohort 1",
          "type": "DRUG"
        },
        {
          "name": "Part 2, Cohort 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2012-06-14",
      "completion_date": "2014-09-04",
      "has_results": false,
      "last_update_posted_date": "2017-08-22",
      "last_synced_at": "2026-11-10T12:13:12.483Z",
      "location_count": 4,
      "location_summary": "New York, New York • Rochester, New York • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01569750"
    },
    {
      "nct_id": "NCT01891643",
      "title": "PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Newly Diagnosed, Previously Untreated Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Elotuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2013-09-30",
      "completion_date": "2020-06-25",
      "has_results": true,
      "last_update_posted_date": "2021-07-01",
      "last_synced_at": "2026-11-10T12:13:12.483Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Hollywood, Florida • Peoria, Illinois + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Marrero",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01891643"
    },
    {
      "nct_id": "NCT00809835",
      "title": "Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cocaine Dependence"
      ],
      "interventions": [
        {
          "name": "Galantamine",
          "type": "DRUG"
        },
        {
          "name": "Computer Assisted Cognitive Behavioral Therapy (CBT)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 120,
      "start_date": "2007-12",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2019-01-30",
      "last_synced_at": "2026-11-10T12:13:12.483Z",
      "location_count": 2,
      "location_summary": "Bridgeport, Connecticut • Stratford, Connecticut",
      "locations": [
        {
          "city": "Bridgeport",
          "state": "Connecticut"
        },
        {
          "city": "Stratford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00809835"
    },
    {
      "nct_id": "NCT01908374",
      "title": "Bioavailability of EPA and DHA From Two Dietary Supplements",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "DHA-rich fish oil versus Phospholipid-rich fish oil",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Arctic Nutrition AS",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 32,
      "start_date": "2013-07",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2013-07-25",
      "last_synced_at": "2026-11-10T12:13:12.483Z",
      "location_count": 1,
      "location_summary": "Addison, Illinois",
      "locations": [
        {
          "city": "Addison",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01908374"
    },
    {
      "nct_id": "NCT03572049",
      "title": "Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Invasive Fungal Infections"
      ],
      "interventions": [
        {
          "name": "SUBA itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Conventional itraconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2018-09-17",
      "completion_date": "2022-04-29",
      "has_results": true,
      "last_update_posted_date": "2023-07-07",
      "last_synced_at": "2026-11-10T12:13:12.483Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03572049"
    }
  ]
}